A5014914760- Chronic Lymphocytic Leukemia Research
- Nutrition and Health in Aging
- Frailty in Older Adults
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Occupational and environmental lung diseases
- Multiple and Secondary Primary Cancers
- Chronic Myeloid Leukemia Treatments
- Inflammatory Myopathies and Dermatomyositis
- Viral-associated cancers and disorders
- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
Centre Hospitalier Universitaire Amiens-Picardie
2017-2023
Inserm
2023
Institut Mondor de Recherche Biomédicale
2023
Université Paris-Est Créteil
2023
Université de Picardie Jules Verne
2017
The use of inotuzumab ozogamicin (InO), a conjugated anti-CD22 monoclonal antibody, is becoming promising frontline treatment for older patients with ALL.
In older patients with cancer, comorbidities compete cancer for cause of death. The objectives were to evaluate mortality and factors associated, according metastatic status.
Monoclonal gammopathy of unknown significance (MGUS), smouldering multiple myeloma (SMM), and (MM) are very common neoplasms. However, it is often difficult to distinguish between these entities. In the present study, we aimed classify most powerful markers that could improve diagnosis by multiparametric flow cytometry (MFC). The study included 348 patients based on two independent cohorts. We first assessed how representative data were in discovery cohort (123 MM, 97 MGUS) then analysed...
In symptomatic Waldenström macroglobulinemia (sWM) patients, prognosis is assessed with the international prognostic scoring system (IPSSWM). follicular lymphoma and other B-cell T-cell lymphomas, disease progression within 24 months (POD24) or (in patients without POD24) after has been proposed as start date for stratifying subsequent survival. present report, we in a large series of 472 sWM value this new dynamic endpoint already reported many lymphomas subtypes. The 3 year survival POD24...
11547 Background: Among older adults with cancer, comorbidities compete cancer as the cause of death. The objectives were to quantify proportion and rate cancer-specific death in patients analyze associations between geriatric factors Methods: Between January 2007 December 2014, prospectively included by ELCAPA cohort study’s eight investigating centers. Competing risk methods used estimate 6-month 3-year mortality rates probe Results: A total 1678 (mean ± standard deviation age: 81.3 5.8;...